[Form 4] Bio-Rad Laboratories, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Colleen Corey, Executive Vice President, Global Human Resources of Bio-Rad Laboratories, reported insider transactions dated 09/01/2025. The filing shows 1,102 shares of Bio-Rad Class A common stock were acquired on vesting of restricted stock units at no cash price, and 398 shares were disposed of at $297.88 per share. Following the transactions, the reporting person beneficially owned 19,581 shares after the vesting event and 19,183 shares after the sale, as shown in the form.

The filing also reports restricted stock unit activity: vesting-related entries of 254, 347, and 501 RSUs tied to prior grants from 2021, 2022, and 2023, with the explanatory note that each RSU represents a contingent right to one share.

Positive

• 1,102 shares issued on RSU vesting, showing alignment of executive compensation with shareholder equity
• Clear disclosure of grant vintages (2021, 2022, 2023) and vesting schedules in the explanatory notes

Negative

• 398 shares sold at $297.88, reducing beneficial ownership from 19,581 to 19,183 shares

Insights

Securities Analyst

TL;DR: Routine executive equity vesting and a partial sale; transactions reflect compensation vesting and a small sale at $297.88 per share.

This Form 4 documents standard compensation-related activity: the vesting of restricted stock units resulting in 1,102 shares issued and a separate sale of 398 shares at $297.88 each. The post-transaction beneficial ownership levels are disclosed, and the explanatory notes tie the RSUs to grants made in 2021-2023 with four-year vesting schedules. For investors, this is a routine insider disclosure with no new operational or financial information about Bio-Rad's business performance.

Corporate Governance Expert

TL;DR: Standard compliance filing showing award vesting and a reported disposition; documentation and vesting schedules are clearly disclosed.

The Form 4 includes clear attribution of the acquired shares to RSU vesting and identifies the reporting person as EVP, Global Human Resources. The form lists grant years (2021, 2022, 2023) and specifies vesting in four equal annual installments beginning on each grant's first anniversary. Signatures and dates are provided, indicating timely filing. This is a routine disclosure consistent with Section 16 reporting requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COREY COLLEEN

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Global Human Resources

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	09/01/2025		M		1,102(1)	A	$0	19,581	D
Bio-Rad A Common Stock	09/01/2025		F		398	D	$297.88	19,183	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	09/01/2025		M			254	(3)	(3)	Bio-Rad A Common Stock	254	$0	0	D
Restricted Stock Units	$0(2)	09/01/2025		M			347	(4)	(4)	Bio-Rad A Common Stock	347	$0	347	D
Restricted Stock Units	$0(2)	09/01/2025		M			501	(5)	(5)	Bio-Rad A Common Stock	501	$0	1,002	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

3. On September 1, 2021, the reporting person was granted 1,013 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

4. On September 1, 2022, the reporting person was granted 1,388 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

5. On September 1, 2023, the reporting person was granted 2,003 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Colleen Corey	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did BIO executive Colleen Corey report on 09/01/2025?

She reported the vesting of 1,102 Class A shares from restricted stock units and a separate disposition of 398 shares at $297.88 per share.

How many Bio-Rad (BIO) shares did Colleen Corey beneficially own after the reported transactions?

Beneficial ownership was reported as 19,581 shares after the vesting event and 19,183 shares after the sale.

What do the restricted stock units (RSUs) represent in this Form 4?

Each RSU represents a contingent right to receive one share of Bio-Rad Class A common stock, per the filing.

Which grant years are associated with the RSUs referenced in the filing?

RSU grants from 2021, 2022, and 2023 are referenced, each vesting in four equal annual installments beginning on the first anniversary of the grant date.

What was the reported sale price per share for the disposed BIO shares?

$297.88 per share for the 398 shares disposed of on 09/01/2025.